Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
XB596, a promising bis-naphthalimide anti-cancer agent.
Chen SF, Behrens DL, Behrens CH, Czerniak PM, Dexter DL, Dusak BL, Fredericks JR, Gale KC, Gross JL, Jiang JB, et al. Chen SF, et al. Among authors: behrens dl. Anticancer Drugs. 1993 Aug;4(4):447-57. doi: 10.1097/00001813-199308000-00005. Anticancer Drugs. 1993. PMID: 8400347
Phospholipase C inhibitors: a new class of cytotoxic agents.
Perrella FW, Chen SF, Behrens DL, Kaltenbach RF 3rd, Seitz SP. Perrella FW, et al. Among authors: behrens dl. J Med Chem. 1994 Jul 8;37(14):2232-7. doi: 10.1021/jm00040a016. J Med Chem. 1994. PMID: 8035430
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P, et al. Kirshenbaum MR, et al. Among authors: behrens dl. Cancer Res. 1994 Apr 15;54(8):2199-206. Cancer Res. 1994. PMID: 8174127 Free article.
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, Diamond M, Dowling R, Grimminger L, Zhang SY, Behrens D, Musselman A, Bruckner R, Zhang M, Jiang X, Hu D, Higley A, Dimeo S, Rafalski M, Mandlekar S, Car B, Yeleswaram S, Stern A, Copeland RA, Combs A, Seitz SP, Trainor GL, Taub R, Huang P, Oliff A. Albright CF, et al. Mol Cancer Ther. 2005 May;4(5):751-60. doi: 10.1158/1535-7163.MCT-05-0006. Mol Cancer Ther. 2005. PMID: 15897239